Glutamate, excitotoxicity, and programmed cell death in parkinson disease

Experimental Neurology

Volumn 220, Issue 2, 2009, Pages 230-233

  Caudle, W Michael ^a   Zhang, Jing ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMPA RECEPTOR ANTAGONIST; DJ 1 PROTEIN; DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LEUCINE RICH REPEAT KINASE 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARKIN; PROTEIN SERINE THREONINE KINASE;

ANOSMIA; APOPTOSIS; ARTICLE; AUTOPHAGY; BRADYKINESIA; CELL DEATH; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; EXCITOTOXICITY; HUMAN; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; RIGIDITY; SYMPTOM; TREMOR;

ANIMALS; AUTOPHAGY; EXCITATORY AMINO ACIDS; GLUTAMIC ACID; HUMANS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION;

EID: 71549151931     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.09.027     Document Type: Note

References (54)

1. Albin R.L., and Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 42 (1992) 733-738
2. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12 (1989) 366-375
3. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., and Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12 (1997) 25-31
4. Ankarcrona M., Dypbukt J.M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S.A., and Nicotera P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15 (1995) 961-973
5. Bandyopadhyay U., and Cuervo A.M. Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein. Exp. Gerontol. 42 (2007) 120-128
6. Battaglia G., Busceti C.L., Pontarelli F., Biagioni F., Fornai F., Paparelli A., Bruno V., Ruggieri S., and Nicoletti F. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45 (2003) 155-166
7. Battaglia G., Busceti C.L., Molinaro G., Biagioni F., Storto M., Fornai F., Nicoletti F., and Bruno V. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 24 (2004) 828-835
8. Bergman H., Wichmann T., and DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 (1990) 1436-1438
9. Bezard E., Boraud T., Bioulac B., and Gross C.E. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11 (1999) 2167-2170
10. Bigford G.E., Alonso O.F., Dietrich D., and Keane R.W. A novel protein complex in membrane rafts linking the NR2B glutamate receptor and autophagy is disrupted following traumatic brain injury. J. Neurotrauma. 26 (2009) 703-720
11. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
12. Breysse N., Baunez C., Spooren W., Gasparini F., and Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 22 (2002) 5669-5678
13. Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., Mugnaini M., Nicoletti F., and Bruno V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci. 27 (2007) 8297-8308
14. Cuervo A.M. Autophagy: many paths to the same end. Mol. Cell. Biochem. 263 (2004) 55-72
15. Cuervo A.M., and Dice J.F. Lysosomes, a meeting point of proteins, chaperones, and proteases. J. Mol. Med. 76 (1998) 6-12
16. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., and Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004) 1292-1295
17. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
18. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51 (1999) 7-61
19. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
20. Gobbel G.T., and Chan P.H. Neuronal death is an active, caspase-dependent process after moderate but not severe DNA damage. J. Neurochem. 76 (2001) 520-531
21. Greenamyre J.T., and Porter R.H. Anatomy and physiology of glutamate in the CNS. Neurology 44 (1994) S7-13
22. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., and Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35 (1994) 655-661
23. Greene J.G., and Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48 (1996) 613-634
24. Hirsch E.C., Hunot S., Faucheux B., Agid Y., Mizuno Y., Mochizuki H., Tatton W.G., Tatton N., and Olanow W.C. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. 14 (1999) 383-385
25. Kingsbury A.E., Mardsen C.D., and Foster O.J. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?. Mov. Disord. 13 (1998) 877-884
26. Klockgether T., Turski L., Honore T., Zhang Z.M., Gash D.M., Kurlan R., and Greenamyre J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30 (1991) 717-723
27. Kosel S., Egensperger R., von Eitzen U., Mehraein P., and Graeber M.B. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. 93 (1997) 105-108
28. Lau Y.S., Trobough K.L., Crampton J.M., and Wilson J.A. Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 21 (1990) 181-187
29. Levy O.A., Malagelada C., and Greene L.A. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14 (2009) 478-500
30. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., and Benabid A.L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339 (1998) 1105-1111
31. Liu W., Liu R., Chun J.T., Bi R., Hoe W., Schreiber S.S., and Baudry M. Kainate excitotoxicity in organotypic hippocampal slice cultures: evidence for multiple apoptotic pathways. Brain Res. 916 (2001) 239-248
32. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison Jr. R.C., and Lau Y.S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956 (2002) 156-165
33. Meredith G.E., Totterdell S., Potashkin J.A., and Surmeier D.J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14 Suppl 2 (2008) S112-115
34. Meredith G.E., Totterdell S., Beales M., and Meshul C.K. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol. 219 (2009) 334-340
35. Michel P.P., Vyas S., Anglade P., Ruberg M., and Agid Y. Morphological and molecular characterization of the response of differentiated PC12 cells to calcium stress. Eur. J. Neurosci. 6 (1994) 577-586
36. Mortimore G.E., Miotto G., Venerando R., and Kadowaki M. Autophagy. Subcell Biochem. 27 (1996) 93-135
37. Olney, J.W., 1990. Excitotoxicity: an overview. Can Dis Wkly Rep 16 Suppl 1E, 47-57; discussion 57-48.
38. Ossowska K., Konieczny J., Wolfarth S., Wieronska J., and Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41 (2001) 413-420
39. Petroske E., Meredith G.E., Callen S., Totterdell S., and Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106 (2001) 589-601
40. Ravikumar B., Duden R., and Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11 (2002) 1107-1117
41. Rodriguez M.C., Obeso J.A., and Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44 (1998) S175-188
42. Rubinsztein D.C. Autophagy induction rescues toxicity mediated by proteasome inhibition. Neuron 54 (2007) 854-856
43. Samara C., Syntichaki P., and Tavernarakis N. Autophagy is required for necrotic cell death in Caenorhabditis elegans. Cell Death Differ. 15 (2008) 105-112
44. Silva R.M., Ries V., Oo T.F., Yarygina O., Jackson-Lewis V., Ryu E.J., Lu P.D., Marciniak S.J., Ron D., Przedborski S., Kholodilov N., Greene L.A., and Burke R.E. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 95 (2005) 974-986
45. Spooren W.P., Gasparini F., Salt T.E., and Kuhn R. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol. Sci. 22 (2001) 331-337
46. Starr M.S. Antiparkinsonian actions of glutamate antagonists-alone and with l-DOPA: a review of evidence and suggestions for possible mechanisms. J. Neural. Transm. Park Dis. Dement. Sect. 10 (1995) 141-185
47. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., and Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. 44 (1998) S142-148
48. Vogiatzi T., Xilouri M., Vekrellis K., and Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283 (2008) 23542-23556
49. Wallace B.A., Ashkan K., Heise C.E., Foote K.D., Torres N., Mitrofanis J., and Benabid A.L. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130 (2007) 2129-2145
50. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., and Rubinsztein D.C. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278 (2003) 25009-25013
51. Wichmann T., and DeLong M.R. Pathophysiology of parkinsonian motor abnormalities. Adv. Neurol. 60 (1993) 53-61
52. Yue Z., Horton A., Bravin M., DeJager P.L., Selimi F., and Heintz N. A novel protein complex linking the delta 2 glutamate receptor and autophagy: implications for neurodegeneration in lurcher mice. Neuron 35 (2002) 921-933
53. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff H.J., Poirier G.G., Dawson T.M., and Dawson V.L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297 (2002) 259-263
54. Yu S.W., Wang H., Dawson T.M., and Dawson V.L. Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol. Dis. 14 (2003) 303-317